July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Characteristics and outcomes of a cohort of primary ocular toxoplasmosis
Author Affiliations & Notes
  • Rabia Bourkiza
    vitreo-retina, Moorfields Eye Hospital, London, United Kingdom
  • Benedict Girling
    Queen Mary University of London, London, United Kingdom
  • Angela Rees
    Moorfields Eye Hospital, London, United Kingdom
  • Carlos Pavesio
    Moorfields Eye Hospital, London, United Kingdom
  • Mark Westcott
    Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships   Rabia Bourkiza, None; Benedict Girling, None; Angela Rees, None; Carlos Pavesio, None; Mark Westcott, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4175. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rabia Bourkiza, Benedict Girling, Angela Rees, Carlos Pavesio, Mark Westcott; Characteristics and outcomes of a cohort of primary ocular toxoplasmosis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4175.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The literature about primary ocular toxoplasmosis is quite limited. The purpose of this study was to explore the clinical features of primary ocular toxoplasmosis and to assess outcomes

Methods : A retrospective review of patients presenting to Moorfields Eye Hospital between 2010 and 2016. Pathology results were searched for raised toxoplasma IgM. Patient records were retrieved to identify cases diagnosed with ocular toxoplasmosis. Data was collected on patients’ demographics, size and location of chorioretinal lesions, anterior chamber and vitreous inflammation, presenting logMAR visual acuity (VA), treatment, and VA at 3 month, 6 month and last follow up.

Results : 21 eyes of 19 patients (11 male; 8 female) with primary ocular toxoplasmosis were identified over the 6 year study period. Mean age was 55.8 (28-74). Three patients were immunocompromised. Twelve (63%) had involvement of the left eye and five (26%) of the right; two (10%) had bilateral involvement. A chorioretinal lesion was present in 20 cases. The size of the lesion was >2 disc diameter (DD) in 6 cases, 2DD in 4, 1DD in 9, 1/2DD in 1. The lesion was in the macular area in 9 cases, in the supratemporal quadrant in 7 cases, infratemporal in 1, supranasal in 2, and infranasal in 1 case. AC inflammation was 3+ in 1 case, 2+ in 3, 1+ in 5, 0.5+ in 3 cases, and there was no AC inflammation in 9 cases. Vitreous inflammation was graded as 3+ in 1 case, 2+ in 6, 1+ in 4, 0.5+ in 1 and no inflammation in 9 cases. Mean IOP at presentation was 15.6mmhg (6-23). Mean presenting VA was 0.55 (0-1.3). Mean follow up was 20.85 (1-67 months). At 3 months, the mean VA was 0.43 (0-1.47), and at final follow up this was 0.73 (0-3). Nine eyes (45%) had <0.3 VA, 6 (30%) had 0.3-1 VA, and 5 (25%) had a VA of > 1. Adverse events at 6 months included retinal detachment in 3 cases and 1 epiretinal membrane. Seventeen patients received oral steroids (30-70mg) with a mean initial dose of 53.75mg and a mean time to <10mg of 7.8 weeks (4-12 weeks). Azithromycin was used in 16 (80%) cases and pyrimethamine in 15 (75%).

Conclusions : In this small retrospective case series primary ocular toxoplasmosis occurred in an older age group and was mainly a normotensive uveitis with mild involvement of the vitreous in most cases. 40% presented with macular involvement, which resulted in high visual morbidity despite widely accepted treatment protocols.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.